leukemia; erythropoietin; transcriptional regulation Erythropoietin (Epo) plays a pivotal role in regulating erythropoiesis through effects on survival, proliferation and differentiation of the erythroid progenitor cells (Wu et al., 1995) . These effects are mediated by binding of Epo to its cognate receptor (EpoR) inducing activation of a series of signaling molecules including kinases, phosphatases and molecular adaptators (Tilbrook and Klinken, 1999) . Accordingly, at least three major signal transduction cascades are initiated: the JAK2/STAT5, the PI3K/AKT and the MAPKinase pathways. Alterations in signaling leading to growth factor independency are frequently observed in leukemic cells.
Spi-1/PU.1 is a master gene in the development of B lymphoid, monocyte and neutrophilic lineages (Scott et al., 1994; Celada et al., 1996; Oikawa et al., 1999) . Ectopic overexpression of spi-1/PU.1 in proerythroblasts leads to cell transformation as demonstrated in transgenic mice overexpressing spi-1/PU.1 in hematopoietic cells. Spi-1-transgenic mice develop an erythroleukemia arising from the proliferation of proerythroblasts arrested in their differentiation (HS1 stage). At disease onset, survival and growth of erythroblasts are under the control of Epo. Thus, the major effect of spi-1 overexpression in transgenic mice is a blockade in the differentiation of the erythroid lineage. Later during disease progression, malignant proerythroblasts characterized by Epo autonomous growth and tumorigenicity in vivo can be isolated (HS2 stage) (Moreau-Gachelin et al., 1996) .
In a study undertaken to define transcriptional signatures distinguishing preleukemic HS1 and malignant HS2 spi-1-transgenic proerythroblasts, we screened genes differentially transcribed between HS1 and HS2 cells using the differential display RT-PCR method (Liang and Pardee, 1997) . Among genes differentially expressed, we focused on one gene coding for phosphatidylinositol 4-phosphatase type II, which was turned on in HS1 cells and off in HS2 cells. The PI-4-phosphatase II was initially isolated from the rat brain as an enzyme that hydrolyses the 4-position phosphate of PtdIns(3,4)P 2 and to a less degree Ins(3,4)P 2 and Ins(1,3,4)P 3 (Norris et al., 1997) . The PtdIns(3,4)P 2 together with PtdIns(3,4,5)P 3 are rapidly produced after PI3 kinase activation (Vanhaesebroeck et al., 2001) . One of their intracellular targets is the kinase Akt/PKB, which is an essential regulator for many biological processes including apoptosis and proliferation ( Vanhaesebroeck and Alessi, 2000) .
Northern blot analysis confirmed that the PI-4-phosphatase II gene was transcribed only in HS1 samples, as a unique 9.5 kb mRNA ( Figure 1a ). As two different PI-4-phosphatases type I (Norris et al., 1995) and type II (Norris et al., 1997) presenting 37% amino-acid identity and exhibiting similar enzymatic activities are characterized, we looked for the expression of type I transcripts on the same cells. We found that PI-4-phosphatase I transcripts were similarly expressed in HS1 and HS2 cells (Figure 1a ). An a-hydrophilic and a b-hydrophobic PI-4-phosphatase II isoform, which differ in their 44 carboxy-terminal residues, are translated from alternatively spliced mRNA variants (Norris et al., 1997) . By RT-PCR using isoform-specific primers (Figure 1c) , we determined that only the a-isoform mRNA was expressed in HS1 cells. Then, we examined PI-4-phosphatase II transcription in various myeloid, erythroid and lymphoid leukemic cell lines (Figure 1b) . Whatever the phenotype of the hematopoietic cell lines, no mRNA was detected by Northern blotting suggesting that PI-4-phosphatase II transcription may be restricted to HS1 cell lines.
The intracellular level of inositol signaling molecules is modulated by several kinases and phosphatases (Toker and Cantley, 1997) . Following cell stimulation by growth factors, intracellular PI3 kinases generate PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 that are second messengers in a variety of signaling pathways (Vanhaesebroeck et al., 2001) including the PI3K/Akt pathway essential for cell growth and survival (Hanada et al., 2004; Song et al., 2005) . These positive effects are counter-balanced by specific lipid phosphatases, including PI-4-phosphatase I and PI-4-phosphatase II, which hydrolyse PtdIns(3,4)P 2 to form PtdIns(3)P (Norris et al., 1995 (Norris et al., , 1997 Ivetac et al., 2005) . It is demonstrated that PI-4-phosphatase I behaves as a negative regulator for megakaryocytes growth (Vyas et al., 2000) and plays a critical function in neurons survival (Nystuen et al., 2001 ). However, PI-4-phosphatase II function remains elusive. To determine the biological consequences of a stable PI-4-phosphatase II expression in leukemic cells, an expression vector containing PI-4-phosphatase IIa cDNA tagged with a c-myc-epitope (MT-PTaseIIa) was introduced into 921 HS2 cells and G418-resistanttransfected clones were selected. Two cell clones (921-MP1 and 921-MP2) were retained for further study. Both expressed a 120 kDa protein corresponding to MT-Ptase IIa which was not detected in cells transfected with an empty vector (921-B1) ( Figure 2a ). When phosphorylated Akt was analyzed by Western blotting with appropriate antibodies, a significant reduction (around 60%) was seen in 921-MP1 and 921-MP2 cells as compared to control 921-B1 cells (Figure 2a) . Thus, Akt activation was reduced in HS2 proerythroblasts when expression of MT-4-phosphatase IIa was forced. In contrast, levels of Erk1/2 activation were similar in 921-MP1, 921-MP2 and 921-B1 cells (Figure 2a ). We next investigated whether the decrease in Akt activation was related to an association of PI-4-phosphatase IIa to the p85 regulatory subunit of PI3-kinase. p85 was immunoprecipitated from 921-MP1, 921-MP2 and 921-B1 cell extracts and the presence of MT-4-phosphatase IIa was assessed by immunoblotting with an anti-Myc-epitope antibody. MT-4-phosphatase IIa was detected in p85 immunoprecipitates from 921-MP1 and 921-MP2 extracts but not from control 921-B1 extracts (Figure 2b ) suggesting that 4-phosphatase IIa may interfere with the activity of the PI3K/Akt pathway through an interaction with p85. As suggested for 4-phosphatase I (Munday et al., 1999) , this association could serve to localize PI-4-phosphatase II to sites where PtdIns(3,4)P 2 is produced by PI3-kinase. The consequences of the constitutive expression of MT-4-phosphatase IIa on growth kinetics and viability of 921-MP1 and 921-MP2 cells were investigated. As compared to control 921-B1 cells, no modifications of these cell characteristics were seen (data not shown) revealing that expression of PI-4-phosphatase IIa is not sufficient to promote reduced cell proliferation and survival. This result makes inconsistent the hypothesis of a tumor-suppressor activity for PI-4-phosphatase II as known for the inositol phosphatase PTEN which dephosphorylates the D3-phosphate of PtdIns(3,4,5)P 3 forming PtdIns(4,5)P 2 and negatively PolyA þ RNAs (2 mg) were isolated and loaded onto 1.2% formaldehyde-agarose gels, then transferred to GeneScreen nylon membranes (Amersham Pharmacia Biotech, UK). After standard prehybridization, membranes were hybridized overnight at 651C with cDNA probes labeled with [a32P] dCTP by using random-primed labeling kit (Amersham, Pharmacia Biotech, UK). Northern blot was probed successively with a rat PI-4-phosphatase II and a murine 4-phosphatase I cDNA probes. RNA loading was controlled by reprobing the blot with a glyceraldehyde-3-phosphate dehydrogenase GAPDH probe. (b) Northern blotting analysis of PI-4-phosphataseII expression in various hematopoietic lineages. PolyA þ mRNAs were prepared from murine B lymphoid (BaF3), human B lymphoid (Raji), T lymphoid (CEM, Jurkat), myeloid (U937, HL60) and erythroid (TF1, HEL, AP217, K562) cell lines. Spi-1-transgenic HS1 and HS2 cell lines were described previously (Moreau-Gachelin et al., 1996) . Northern blot was probed successively with the rat 4-phosphataseII and the GAPDH probe as control. (c) RT-PCR analysis of the transcription of PI-4-phosphatase IIa and PI-4-phosphatase IIb in HS1 and HS2 cells. DNAs were amplified with specific primers for PI-4-phosphatase IIa, PI-4-phosphatase IIb or GAPDH as control.
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controls the PI3K/Akt signaling pathway (Maehama and Dixon, 1998) . Although it cannot be excluded that the absence of PI-4-phosphatase IIa expression in HS2 cells may participate in the malignant phenotype of the proerythroblast by maintaining an elevated intracellular level of PtdIns(3,4)P 2 and a sustained activation of Akt, our data do not substantiate a causative role for the extinction of PI-4-phosphatase II gene transcription in the progression of erythroleukemia. Our results are in contrast to the effects of PI-4-phosphatase I, which negatively regulates the cell growth of primary megacaryocytes and NIH3T3 cells (Vyas et al., 2000) . This discrepancy might result from the differences in cell types and/or in intrinsic functions of PI-4-phosphatases I and II. However, it is most likely that other oncogenic mechanisms in HS2 cells by-pass putative effects of maintaining PI-4-phosphatase IIa expression.
The growth of HS2 cells is Epo-independent. Previously, we reported that EpoR is resting in these cells, but become phosphorylated in response to Epo stimulation (Barnache et al., 2001) . To investigate whether the absence of PI-4-phosphatase II transcripts in HS2 cells resulted from the fact that EpoR was not activated, 606 HS2 cells were cultured in the presence of Epo and PI-4-phosphatase II expression was monitored by RT-PCR. Indeed, PI-4-phosphatase II transcription was induced by Epo (Figure 2c ). Transcripts were seen within 15 min following Epo stimulation with a maximal level reached in 18 h (Figure 2d) . Same results were observed with 921 HS2 cells (not shown). We conclude that silencing of PI-4-phosphatase II transcription results from the inactivity of the EpoR in HS2 cells. We extended our analysis to determine whether Epo could also participate in PI-4-phosphatase II transcriptional control in an human leukemic cell line UT7 (Komatsu et al., 1991) , which is Epo-dependent for the proliferation and survival. Figure 2e shows that (Yoshimura et al., 1995) . Our results further support the view that PI-4-phosphatase IIa may act as a negative feedback factor for Epo signaling by interfering with the PI3K/Akt signaling pathway. This potential novel role for PI-4-phosphatase IIa in proerythroblast remains to be explored. Moreover, PI-4-phosphatase II gene is reported to be expressed in various tissues, including brain, muscle and pancreas (Norris et al., 1997) . Further studies will be required to determine whether the transcriptional regulation of PI-4-phosphatase II gene by growth factors is a generic mechanism or whether it is restricted to erythroid cell type.
